GSK3B and acute kidney injury: Regarding the involvement of GSK-3β in controlling TNF-α expression [17,50] as well as TNF-α receptor signaling [14,51], it is hypothesized that GSK-3β inhibition ameliorates cisplatin-induced AKI through a mechanism involving the blockade of the TNF-α response.